Literature DB >> 23307426

3-[(6-Arylamino)pyridazinylamino]benzoic acids: design, synthesis and in vitro evaluation of anticancer activity.

Khaled A M Abouzid1, Nadia A Khalil, Eman M Ahmed, Khaled Omar Mohamed.   

Abstract

A series of novel substituted 3,6-disubstituted pyridazines based on the structure of vatalanib (PTK787) were designed and synthesized. The cytotoxicity of the final compounds was tested in vitro on HT-29 colon cancer cell line. Compounds 2a and 2b with 4-chlorophenylamino moiety, exerted the highest cytotoxic activity with IC(50) values equal to 15.3 and 3.9 μM respectively. The most promising compound, 2b, was found to be about fivefold more active than vatalanib against HT-29 colon cancer cell line.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23307426     DOI： 10.1007/s12272-013-0007-8

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN： 0253-6269            Impact factor:   4.946


  3 in total

1.  Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.

Authors:  Ahmed Sabt; Wagdy M Eldehna; Tarfah Al-Warhi; Ohoud J Alotaibi; Mahmoud M Elaasser; Howayda Suliman; Hatem A Abdel-Aziz
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

2.  Synthesis of Some New Pyridazine Derivatives for Anti-HAV Evaluation.

Authors:  Eman M Flefel; Waled A Tantawy; Walaa I El-Sofany; Mahmoud El-Shahat; Ahmed A El-Sayed; Dina N Abd-Elshafy
Journal:  Molecules       Date:  2017-01-17       Impact factor: 4.411

3.  SABRE hyperpolarized anticancer agents for use in 1 H MRI.

Authors:  Elizabeth J Fear; Aneurin J Kennerley; Peter J Rayner; Philip Norcott; Soumya S Roy; Simon B Duckett
Journal:  Magn Reson Med       Date:  2022-03-07       Impact factor: 3.737
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.